Summary

In a study published in Science Translational Medicine , a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences developed PRINCE and Little Prince, dual small-molecule-controlled genome editing systems that allow CRISPR activity to be switched on by drug inducers and kept largely silent in their absence. Current therapeutic CRISPR strategies often rely on passive control: RNA or protein editors are delivered, act for a limited time, and gradually disappear as they degrade.

AI summaries can be wrong sometimes—always verify important details using the source article.